SCHEMBL30749150

SCHEMBL30749150

CC1(C)C(=O)N(c2cnc(N3CCC(F)(F)C3)nc2)c2nc(CO)nc(NC3CCC3)c21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 6/20 0.41
WHR1 P49842 1/20 0.34
ACACB O00763 4/20 0.34
CNR2 P34972 2/20 0.33
NR2F2 P24468 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
PDE10A Q9Y233 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
S1PR2 O95136 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
XBP1 P17861 1/20 0.32
RAB9A P51151 1/20 0.32
PPP1CA P62136 1/20 0.32
KMT2A Q03164 1/20 0.32
CHRM3 P20309 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748745 0.89 ACACB (0.35) SYKACACBCNR2PDE10ATRPV3
SCHEMBL31691334 0.83 HDAC6 (0.34) SYKNR2F2NPSR1KDM4EMAPT
SCHEMBL30748798 0.78 MAPK1 (0.33) SYKMAPK1
SCHEMBL31691422 0.76 CHRM3 (0.37) SYKNR2F2NPSR1KDM4EMAPT
SCHEMBL30749004 0.75 HDAC6 (0.33) SYKNR2F2NPSR1KDM4EMAPT
SCHEMBL31691369 0.75 ACACB (0.33) ACACBCNR2
SCHEMBL30748918 0.75 TAF1 (0.34) SYK
SCHEMBL30748902 0.75 TRPV3 (0.35) SYKACACBADRA1ATRPV3
SCHEMBL30749136 0.74 ACACB (0.37) ACACBCNR2PDE10AADRA1A
SCHEMBL30748916 0.72 HDAC6 (0.34) SYKMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT SYK 2316/4885WHR1 2865/4885ACACB 1127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.